Results 171 to 180 of about 2,262 (198)
Some of the next articles are maybe not open access.
Expert Opinion on Drug Metabolism and Toxicology, 2018 Sebastian Marciano, Isabella Esposito
exaly +3 more sources
Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection
Infectious Diseases and Therapy, 2018 Yash Gandhi, Tushar Garimella, Li Zhu
exaly +2 more sources
Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C [PDF]
Journal of Gastroenterology, 2016 Background: HCV infection in chronic hemodialysis patients is high, has a poor prognosis and high risk of renal graft failure, and requires nosocomial infection control measures.
Mitsuteru Natsuizaka +2 more
exaly +2 more sources
Asunaprevir and daclatasvir in hemodialysis patients with chronic hepatitis C virus genotype 1b infection [PDF]
JGH Open, 2017 Iwata Ozaki
exaly +2 more sources
Journal of Comparative Effectiveness Research, 2018 Aim: To evaluate the cost–effectiveness of the novel all-oral direct-acting antiviral regimen daclatasvir + asunaprevir (DUAL), versus interferon-based regimens for the treatment of chronic hepatitis C virus genotype 1b infection.
Peter Feng Wang +6 more
exaly +2 more sources
Asunaprevir for hepatitis C: a safety evaluation
Expert Opinion on Drug Safety, 2015The introduction of direct-acting antiviral (DAA) agents has revolutionized the treatment of hepatitis C virus (HCV) chronic infection. Non-structural 3 protease inhibitors are currently the most numerous class of DAAs on the market.This review mainly focuses on the tolerability and safety profile of asunaprevir (ASV)-containing DAA regimens.
GENTILE, Ivan +4 more
openaire +3 more sources
Daclatasvir + Asunaprevir: First Global Approval
Drugs, 2014The combination of daclatasvir + asunaprevir [Daklinza(®) + Sunvepra(®) (Japan)], two direct-acting antiviral agents, has been developed by Bristol-Myers Squibb for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 infections, including those with compensated cirrhosis.
openaire +2 more sources